Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)
China · Delayed Price · Currency is CNY 36.95
+0.19 (0.52%)
At close: Mar 6, 2026
Hangzhou Biotest Biotech Revenue
In the year 2025, Hangzhou Biotest Biotech had annual revenue of 448.37M CNY, down -19.85%. Hangzhou Biotest Biotech had revenue of 140.30M in the quarter ending December 31, 2025, a decrease of -17.77%.
Revenue
448.37M
Revenue Growth
-19.85%
P/S Ratio
12.06
Revenue / Employee
743.57K
Employees
622
Market Cap
5.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 448.37M | -111.03M | -19.85% |
| Dec 31, 2024 | 559.40M | 117.29M | 26.53% |
| Dec 31, 2023 | 442.11M | -1.46B | -76.75% |
| Dec 31, 2022 | 1.90B | 83.07M | 4.57% |
| Dec 31, 2021 | 1.82B | 952.70M | 110.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novogene | 2.17B |
| Wuhan Hvsen Biotechnology | 1.67B |
| Kexing Biopharm | 1.54B |
| Pulike Biological Engineering | 1.10B |
| ChemPartner PharmaTech | 1.07B |
| Beijing Bohui Innovation Biotechnology Group | 834.38M |
| GemPharmatech | 793.25M |
| PharmaResources (Shanghai) | 667.47M |